ValueQ4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses181 M132 M158 M155 M626 MResearch & development31 M22 M21 M33 M107 MOperating income40 M66 M72 M43 M221 MNon-Operating Income, Total4 M5 M10 M3 M22 MInterest expense, net of interest capitalized12 M10 M11 M11 M44 MNon-Operating Income, excl. Interest Expenses-8 M-5 M-1 M-8 M-22 MUnusual income/expense—————Pretax income-4 M59 M62 M37 M154 MEquity in earnings—————Taxes15 M11 M45 M-5 M66 MNon-controlling/minority interest—————After tax other income/expense01 M01 M2 MNet income before discontinued operations16 M47 M18 M43 M124 MDiscontinued operations—————Net income16 M47 M18 M43 M124 MDilution adjustment—————Preferred dividends—————Diluted net income available to common stockholders-12 M47 M18 M42 M95 MBasic earnings per share (Basic EPS)0.130.380.150.341Diluted earnings per share (Diluted EPS)0.130.380.140.330.98Average basic shares outstanding132 M124 M125 M125 M506 MDiluted shares outstanding133 M125 M125 M127 M510 MEBITDA58 M71 M71 M47 M247 MEBIT40 M66 M71 M44 M221 MCost of revenue48 M44 M52 M83 M227 MOther cost of goods sold—————Depreciation & amortization (cash flow)18 M5 M03 M26 M
Indivior Pharmaceuticals Inc
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.